"Sonablate® prostate ablation is a key component of personalized precision prostate care in my urology practice." - Dr. Stephen Scionti
Charlotte, NC (PRWEB) December 08, 2015
SonaCare Medical, LLC reports that two Sonablate® HIFU procedures were performed on Friday, December 4th, by Dr. Stephen Scionti in Sarasota, Florida. Dr. Scionti is collaborating with Vituro Health to bring their HIFU treatment program to the Sarasota Interventional Radiology Center. This facility becomes the third location, among six systems installed to date, to perform a Sonablate® HIFU prostate tissue ablation procedure in the United States since the device received regulatory authorization in October. Dr. Scionti and team have another procedure scheduled for today, and plan to have ten performed before December 25th.
As a long-time advocate for HIFU technology Dr. Scionti comments, "Sonablate® technology offers me the ability to create a customized MRI Fusion guided targeted ablation for my patients, offering them precise prostate ablation with a high likelihood of maintaining normal function. Sonablate® prostate ablation is a key component of personalized precision prostate care in my urology practice. I have collaborated with SonaCare Medical for nearly a decade and have seen dramatic HIFU technology improvements. As Medical Director for Vituro Health, I am excited to be able to offer this space age technology to my patients and to train other urologists on how to perform advanced prostate Sonablate® ablation techniques."
Prior to the technology’s acceptance in the United States, Dr. Stephen Scionti brought his patients to international procedure locations, facilitated by SonaCare Medical’s subsidiary company, International HIFU. Dr. Scionti has performed well over 600 procedures, and was a regular participant in and speaker at the International HIFU Center of Excellence educational conferences in Nassau, Bahamas.
SonaCare Medical's Chief Executive Officer, Dr. Mark Carol, adds, “Steve has been a longtime supporter of focused ultrasound ablation in general, and Sonablate® technology specifically. It is very exciting and gratifying to see Dr. Scionti launch his HIFU program in the U.S. after so many years of delivering treatments outside the U.S. Furthermore, his pioneering use of image guided technology will allow a wide range of patients to experience the reported benefits of a focal prostate ablation.”
Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate® technology has been used around the world on nearly 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S.
About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.
For additional information, visit http://www.SonaCareMedical.com
SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)SonaCareMedical.com
Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.